Christopher Peetz Sells 7,489 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 7,489 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the sale, the chief executive officer now directly owns 119,359 shares in the company, valued at approximately $5,110,952.38. This represents a 5.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Mirum Pharmaceuticals Stock Performance

MIRM opened at $42.00 on Friday. The firm has a fifty day moving average price of $42.93 and a 200 day moving average price of $40.62. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $48.89. The stock has a market cap of $2.02 billion, a P/E ratio of -20.79 and a beta of 0.98. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $90.38 million during the quarter, compared to the consensus estimate of $81.99 million. During the same quarter in the prior year, the firm posted ($0.57) earnings per share. The company’s revenue was up 89.4% compared to the same quarter last year. Equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.46 earnings per share for the current year.

Analyst Ratings Changes

MIRM has been the topic of a number of research analyst reports. Robert W. Baird boosted their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Citigroup increased their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Leerink Partners lifted their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $57.10.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. State Street Corp raised its stake in shares of Mirum Pharmaceuticals by 19.9% during the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after buying an additional 297,511 shares during the period. Rice Hall James & Associates LLC lifted its holdings in Mirum Pharmaceuticals by 6.9% during the second quarter. Rice Hall James & Associates LLC now owns 229,730 shares of the company’s stock valued at $7,854,000 after purchasing an additional 14,843 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Mirum Pharmaceuticals by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock valued at $12,798,000 after purchasing an additional 17,149 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Mirum Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after purchasing an additional 29,017 shares during the period. Finally, Bank of New York Mellon Corp raised its position in shares of Mirum Pharmaceuticals by 48.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 143,000 shares of the company’s stock worth $4,889,000 after purchasing an additional 46,506 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.